Futura Medical (GB:FUM) has released an update.
Futura Medical PLC, a developer of innovative sexual health products, has announced that its total issued share capital stands at 301,863,641 Ordinary Shares, with an equal number of voting rights available to shareholders. The company, which is known for its leading product Eroxon—a topical gel treatment for erectile dysfunction—has secured distribution partners across major consumer markets, including the US and Europe. Eroxon has already garnered industry recognition, winning multiple healthcare awards.
For further insights into GB:FUM stock, check out TipRanks’ Stock Analysis page.
